巴曲酶敏感程度与全频下降型突发性聋预后的相关性

发布时间：2018-06-30 02:21

本文选题：突发性聋 + 巴曲酶　；参考：《实用医学杂志》2017年11期

【摘要】：目的:探讨巴曲酶敏感程度与全频下降型突发性聋患者预后的相关性。方法:收集本院收住入院的单侧全频下降型突发性耳聋患者112例(排除全聋及接近全聋患者),根据患者对巴曲酶首剂治疗后血纤维蛋白原的变化分为敏感组及不敏感组,比较两组患者听力改善程度及治疗效果。同时设其他药物使用相同但未使用巴曲酶治疗患者28例作为对照组。结果:使用巴曲酶患者听力改善程度及治疗效果优于未使用巴曲酶治疗患者(P0.05),巴曲酶敏感组患者听力改善程度及治疗效果明显优于不敏感组(P0.05)。结论:使用巴曲酶能改善全频下降型突发性聋的预后,巴曲酶敏感患者使用巴曲酶治疗后其预后更好,但具体作用原理需进一步研究探讨。
[Abstract]:Objective: to investigate the relationship between the sensitivity of batroxobin and the prognosis of patients with fully-frequency descending sudden deafness. Methods: 112 patients with unilateral full-frequency descending sudden deafness (excluding all deafness and close to full deafness) were collected and divided into sensitive group and insensitive group according to the changes of fibrinogen after first dose of batroxobin. The degree of hearing improvement and therapeutic effect were compared between the two groups. At the same time, 28 patients were treated with the same drug but no batroxobin as control group. Results: the hearing improvement degree and therapeutic effect of batroxobin group were better than that of non-batroxobin group (P0.05), and the hearing improvement degree and therapeutic effect of batroxobin sensitive group were significantly better than that of insensitive group (P0.05). Conclusion: batroxobin can improve the prognosis of fully-frequency descending sudden deafness, and the prognosis of batroxobin sensitive patients is better than that of batroxobin, but the mechanism of batroxobin needs further study.
【作者单位】：浙江省湖州市中心医院耳鼻咽喉科;
【基金】：浙江省医药卫生科技计划项目(编号:2016KYB024)
【分类号】：R764.437

【参考文献】